San Carlos, Calif.
Went public 8/3/2000 at $15 per share
Filing Range: 7 mil. shares @ $13 to $15
Shares Outstanding: 28.8 mil. shares
Underwriters: Salomon Smith Barney/Robertson Stephens & Co./U.S.
Bancorp Piper Jaffray
Company Counsel: Pillsbury Madison & Sutro
Manager Counsel: Cravath, Swaine & Moore
Auditor: PricewaterhouseCoopers LLP
Focuses on using mouse molecular genetics to unlock the “in vivo” function of novel genes in order to develop new therapeutic targets. The company develops so-called “knockout” mouse clones (mice that lack the specific gene.) Using special technology, the company then determines the impact of that gene on the phenotype, the physical expression of an organism’s genetic composition.
Baccharis Capital Inc.
Boston Millennia Partners
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 07/08/1998 6 Early Stage 11500.0
2 01/31/2000 4 Expansion 22549.0
(Data in $ millions)
Total Revenues: $1.2
Net Income: -13.8